You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,603,910


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,603,910
Title:Pharmaceutical compositions containing hyaluronic acid and collagenase for the topical treatment of wounds, burns and ulcers
Abstract: The present invention concerns new compositions containing hyaluronic acid or the derivatives thereof in association with the proteolytic enzyme collagenase (and relative pharmaceutical formulations) for the preparation of a dressing for topical treatment of various kinds of wounds, burns of varying depth, pressure sores, vascular ulcers and diabetic foot ulcers as well as for the treatment of hypertrophic and keloid scars.
Inventor(s): Vaccaro; Susanna (Abano Terme-Padua, IT), Gennari; Giovanni (Abano Terme-Padua, IT), Callegaro; Lanfranco (Abano Terme-Padua, IT), Giannelli; Antonio (Abano Terme-Padua, IT), Caruso; Salvatore (Abano Terme-Padua, IT)
Assignee: FIDIA FARMACEUTICI S.p.A. (Abano Terme, Padua, IT)
Application Number:14/481,615
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,603,910
Patent Claims:1. A method of treating Dupuytren's contracture which comprises administering to a subject having Dupuytren's contracture a pharmaceutical composition comprising hyaluronic acid or at least one hyaluronic acid derivative and the proteolytic enzyme collagenase, wherein said collagenase is from the non-pathogenic micro-organism belonging to the strain Vibrio Alsinolyticus sub. lophagus, wherein said hyaluronic acid derivative is at least one member selected from the group consisting of salts of hyaluronic acid with organic and/or inorganic bases, amides, sulphatated derivatives, and deacetylated and percarboxylated derivatives, and wherein the concentration of the proteolytic enzyme collagenase is between 0.01 U and 100 U/milligrams of said hyaluronic acid or said hyaluronic acid derivative, said hyaluronic acid or said hyaluronic acid derivative is present in a concentration of between 0.01 and 5% weight/weight of the composition and wherein said hyaluronic acid or the hyaluronic acid used in the preparation of its derivative has a molecular weight of between 50 kDa and 200 kDa; wherein the hyaluronic acid acts to reduce the rate of the proteolytic activity of the collagenase in the subject.

2. The method according to claim 1, wherein said pharmaceutical composition further comprises an additional pharmacologically and/or biologically active substance.

3. The method according to claim 1, wherein the concentration of the enzyme collagenase ranges between 0.1 and 20 U/milligrams of said hyaluronic acid or of said hyaluronic acid derivative.

4. The method according to claim 1, wherein the concentration of the enzyme collagenase is between 0.2 and 10 U/milligrams of said hyaluronic acid or of said hyaluronic acid derivative.

5. The method according to claim 1, wherein the concentration of said hyaluronic acid or of said hyaluronic acid derivative is between 0.1 and 2% w/w.

6. The method according to claim 4, wherein the concentration of said hyaluronic acid or of said hyaluronic acid derivative is between 0.2 and 0.4% w/w.

7. The method according to claim 5, wherein said composition further comprises maltose and/or carrageenan as a stabilizing agent.

8. A method for treating Dupuytren's contracture which comprises administering to a subject having Dupuytren's contracture a pharmaceutical composition comprising (a) hyaluronic acid or at least one hyaluronic acid derivative, (b) the proteolytic enzyme collagenase, and (c) maltose and carrageenan as stabilizing agents, wherein said collagenase is from the non-pathogenic microorganism belonging to the strain Vibrio Alginolyticus sub. lophagus, wherein said hyaluronic acid derivative is at least one member selected from the group consisting of salts of hyaluronic acid with organic and/or inorganic bases, amides, sulphatated derivatives, and deacetylated and percarboxylated derivatives, and wherein the concentration of the proteolytic enzyme collagenase is between 0.01 U and 100 U/milligrams of said hyaluronic acid or said hyaluronic acid derivative, said hyaluronic acid or said hyaluronic acid derivative is present in a concentration of between 0.01 and 5% weight/weight of the composition wherein said hyaluronic acid or the hyaluronic acid used in the preparation of its derivative has a molecular weight of between 50 kDa and 200 kDa, and wherein the hyaluronic acid acts to reduce the rate of the proteolytic activity of the collagenase in the subject.

9. A method for treating Dupuytren's contracture which comprises administering to a subject having Dupuytren's contracture a pharmaceutical composition comprising (a) hyaluronic acid or at least one hyaluronic acid derivative, (b) the proteolytic enzyme collagenase, and (c) maltose and carrageenan as stabilizing agents, wherein said collagenase is from the non-pathogenic microorganism belonging to the strain Vibrio Alginolyticus sub. lophagus, wherein said hyaluronic acid derivative is at least one member selected from the group consisting of salts of hyaluronic acid with organic and/or inorganic bases, amides, sulphatated derivatives, and deacetylated and percarboxylated derivatives, and wherein the concentration of the proteolytic enzyme collagenase is between 0.02 U and 20 U/milligrams of said hyaluronic acid or said hyaluronic acid derivative, said hyaluronic acid or said hyaluronic acid derivative is present in a concentration of between 0.01 and 5% weight/weight of the composition wherein said hyaluronic acid or the hyaluronic acid used in the preparation of its derivative has a molecular weight of between 50 kDa and 200 kDa, and wherein the hyaluronic acid acts to reduce the rate of the proteolytic activity of the collagenase in the subject.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.